Scarica l'app Stockscreener
132.65
2.72%
-3.71
Dopo l'orario di chiusura:
132.90
0.25
+0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$136.36
Aprire:
$136.36
Volume 24 ore:
1.56M
Relative Volume:
1.10
Capitalizzazione di mercato:
$19.45B
Reddito:
$9.61B
Utile/perdita netta:
$1.53B
Rapporto P/E:
12.68
EPS:
10.46
Flusso di cassa netto:
$1.85B
1 W Prestazione:
-4.65%
1M Prestazione:
+2.61%
6M Prestazione:
-5.17%
1 anno Prestazione:
-35.04%
Intervallo 1D:
$132.04
$136.36
Intervallo di 1 settimana:
$132.04
$142.32
Portata 52W:
$110.03
$206.70
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
132.65 | 19.99B | 9.61B | 1.53B | 1.85B | 10.46 |
|
LLY
Lilly Eli Co
|
731.96 | 658.15B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
175.45 | 425.77B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
207.92 | 367.55B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.47 | 245.64B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
83.21 | 209.99B | 63.43B | 16.42B | 14.72B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
What does recent volatility data suggest for Biogen Inc.Options Play & Long-Term Capital Growth Ideas - Newser
Price T Rowe Associates Inc. MD Sells 782,524 Shares of Biogen Inc. $BIIB - MarketBeat
Visualizing Biogen Inc. stock with heatmapsJuly 2025 Movers & Reliable Volume Spike Alerts - Newser
HighTower Advisors LLC Has $1.60 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Purchased by Korea Investment CORP - MarketBeat
US FDA’s ARIA Analysis Adds Earlier Scan To Biogen/Eisai Leqembi Label - insights.citeline.com
Is Biogen Inc. stock ready for a breakoutRecession Risk & Technical Pattern Recognition Alerts - Newser
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
FDA recommends more monitoring of Alzheimer's patients on Eisai-Biogen's drug Leqembi - Reuters
FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi - Reuters
Regulatory Vigilance and the Future of Biogen’s Leqembi: Balancing Innovation with Risk in Alzheimer’s Drug Development - AInvest
Will a bounce in Biogen Inc. offer an exit2025 Technical Patterns & Real-Time Buy Signal Notifications - Newser
Evaluating Biogen Inc. with trendline analysisTrade Risk Summary & Expert Curated Trade Setup Alerts - Newser
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study - Benzinga
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Stock Analysis | Biogen OutlookNavigating Bearish Signals Amid Mixed Analyst Sentiment - AInvest
Biogen Inc. stock chart pattern explainedJuly 2025 Recap & Fast Entry Momentum Alerts - Newser
Custom watchlist performance reports with Biogen Inc.Quarterly Profit Report & Stepwise Entry/Exit Trade Alerts - Newser
Biogen Inc. $BIIB Shares Purchased by FORA Capital LLC - MarketBeat
Altrinsic Global Advisors LLC Reduces Stake in Biogen Inc. $BIIB - MarketBeat
Causeway Capital Management LLC Raises Stock Position in Biogen Inc. $BIIB - MarketBeat
Synovus Financial Corp Grows Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Campbell & CO Investment Adviser LLC Reduces Stock Position in Biogen Inc. $BIIB - MarketBeat
APG Asset Management N.V. Sells 9,014 Shares of Biogen Inc. $BIIB - MarketBeat
Will Biogen Inc. stock go up soon2025 Market Overview & Fast Moving Market Watchlists - Newser
Developing predictive dashboards with Biogen Inc. data2025 Top Decliners & Low Risk Growth Stock Ideas - Newser
Can volume confirm reversal in Biogen Inc.July 2025 Earnings & Consistent Growth Equity Picks - Newser
Biogen Inc. stock daily chart insights2025 Institutional Moves & Weekly Breakout Opportunity Watchlist - Newser
Biogen’s Zurzuvae and the Expanding Postnatal Depression Treatment Market: A Catalyst for Long-Term Growth in Maternal Mental Health - AInvest
Biogen Inc. $BIIB Shares Sold by Northern Trust Corp - MarketBeat
Level Four Advisory Services LLC Buys 8,685 Shares of Biogen Inc. $BIIB - MarketBeat
Multi factor analysis applied to Biogen Inc.2025 Top Gainers & Verified Entry Point Signals - Newser
Dimensional Fund Advisors LP Reduces Holdings in Biogen Inc. $BIIB - MarketBeat
Quantbot Technologies LP Grows Position in Biogen Inc. $BIIB - MarketBeat
UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression - MSN
Biogen Dips 0.26% as $0.19B Volume Ranks 491st in Market Activity Amid Global Smart Shelves Market Surge - AInvest
Can trapped investors hope for a rebound in Biogen Inc.Earnings Miss & Real-Time Volume Analysis Alerts - Newser
Biogen wins approval of postpartum depression drug Zurzuvae in UK - Seeking Alpha
Analyzing drawdowns of Biogen Inc. with statistical toolsEarnings Overview Summary & Weekly Sector Rotation Insights - Newser
Biogen Partnership and Zorevunersen Data Could Be a Game Changer for Stoke Therapeutics (STOK) - simplywall.st
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):